Ondexxya is the first approved reversal agent specifically for Factor Xa inhibitors, providing a major advance in the treatment of patients hospitalised with life-threatening bleeding
India accounts for more than half (almost 60%) of new leprosy cases worldwide, despite being declared ‘leprosy-free’ in 2005.
The registry will be conducted for approximately two and a half years and up to 200 subjects will be enrolled
The summit also saw the launch of two important reports- Multi-Regional Clinical Trials (MRCT) and Value of OTC in India
A novel second-generation approach to achieve a safe, durable, and stable transgene expression to overcome the challenges of factor VIII replacement therapies
Technology Development Board supports commercialisation of Metal Injection Molding of implants
Ozempic is now approved in the US at 0.5 mg,1.0 mg and 2.0 mg doses for the treatment of type 2 diabetes in adults
Dupixent peak sales ambition raised to more than €13 billion
The amalgamation will integrate business operations and provide impetus to the existing portfolio of Alembic
50 µg dose approved for all adults over 50 years of age and immunocompromised adults over 18 years of age
Subscribe To Our Newsletter & Stay Updated
